Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report

doi:10.5306/wjco.v16.i3.99527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (123)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Sum=58

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=43

Publishing Process of This Article

Item

Count

Browse

Download

Sum=16

Mar 24, 2025 (publication date) through Jan 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Mar 24, 2025; 16(3): 99527
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.99527

Open in New Tab Full Size Figure Download Figure

Figure 1 Treatment timeline. CapeOX regimen includes oxaliplatin and capecitabine. FOLFIRI regimen includes irinotecan, leucovorin, and fluorouracil. PD: Progressive disease; PR: Partial response.

Open in New Tab Full Size Figure Download Figure

Figure 2 Computed tomography images. A: Evidence of liver metastatic disease after surgery (November 2023); B: Liver metastasis progression after FOLFIRI plus bevacizumab regimen (March 2024); C: Partial remission of liver metastases after disitamab vedotin-containing therapy (June 2024); D: Continuous remission of liver metastases after disitamab vedotin-containing therapy (September 2024).

Open in New Tab Full Size Figure Download Figure

Figure 3 Changes in serum carcinoembryonic antigen levels (ng/mL) from December 2023 to November 2024. CEA: Carcinoembryonic antigen.

Citation: Yan HC, Liu Y, Feng Y, Li JM, Sheng LM, Chen X, Xie YP, Li N. Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report. World J Clin Oncol 2025; 16(3): 99527
URL: https://www.wjgnet.com/2218-4333/full/v16/i3/99527.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i3.99527